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Because of their ease of isolation and relative abundance, adipose-derived mesenchymal stem cells (ASCs) are a
particularly attractive autologous cell source for various therapeutic purposes. ASCs retain a high proliferation capacity
in vitro and have the ability to undergo extensive differentiation into multiple cell lineages. Moreover, ASCs
secrete a wide range of growth factors that can stimulate tissue regeneration. Therefore, the clinical use of ASCs is
feasible. However, the potential of ASCs differs depending on the donor’s medical condition, including diseases
such as diabetes. Recent studies demonstrated that ASCs from diabetic donors exhibit reduced proliferative
potential and a smaller proportion of stem cell marker-positive cells. Therefore, to ensure the success of regenerative
medicine, tissue engineering methods must be improved by the incorporation of factors that increase the proliferation
and differentiation of stem/progenitor cells when autologous cells are used. Platelet-rich plasma (PRP), which contains
high levels of diverse growth factors that can stimulate stem cell proliferation and cell differentiation in the context of
tissue regeneration, has recently been identified as a biological material that could be applied to tissue regeneration.
Thus, co-transplantation of ASCs and PRP represents a promising novel approach for cell therapy in regenerative
medicine. In this review, we describe the potential benefits of adding PRP to ASCs and preclinical and clinical studies of
this approach in various medical fields. We also discuss the mechanisms of PRP action and future cell-based therapies
using co-transplantation of ASCs and PRP.Review
Mesenchymal stem cells (MSCs) represent independent
populations of stem cells with self-renewing properties
and an established multipotent differentiation profile
in vitro [1, 2]. Furthermore, they have several advan-
tages in regard to clinical applications for the purpose
of repairing or regenerating damaged tissues, especially
because they avoid the ethical issues raised by the use
of embryonic stem cells [3].
Numerous clinical studies using MSCs have been per-
formed in various fields. Autologous MSCs represent an
attractive source for cell-based regenerative medicine
because these immature cells are present in the bone
marrow, peripheral blood, menstrual blood, and nearly* Correspondence: hmizuno@juntendo.ac.jp
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dermis, periosteum, and deciduous teeth), as well as in
solid organs (for example, liver, spleen, and lung) [4–6].
In particular, adipose-derived stem cells (ASCs) obtained
from lipoaspirates have multilineage potential; that is,
they are capable of differentiating into adipogenic,
chondrogenic, myogenic, osteogenic, and neurogenic
cells [7, 8]. Thus, ASCs could be used in clinical appli-
cations for the repair of damaged tissues, as well as for
angiogenic therapy. Injection of human ASCs was re-
cently shown to induce osteoid matrix formation and
improve neovascularization in an ischemic hind limb in
immunotolerant mice [9–11]. Similarly, ASCs can in-
crease the functional capacity of damaged skeletal
muscle in vivo [12]. Moreover, ASCs are abundant and
easy to harvest from patients’ inguinal fat pads.is distributed under the terms of the Creative Commons Attribution 4.0
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promising approach for regenerating damaged tissues, the
detailed mechanisms underlying the regenerative pathways
of transplanted ASCs are not clearly understood. Recent
publications have suggested that ASC differentiation may
not be the main regenerative mechanism in cell therapy,
although the multipotent characteristics of these prepa-
rations have been demonstrated in vitro and have
attracted the greatest attention from the standpoint of
their use in tissue engineering approaches. Most of the
beneficial effects of stem cells might be attributed to
soluble factors released from stem cells [3]. However,
several groups report that ASCs derived from different
tissues not only share many similarities but also seem
to exhibit differences in terms of marker expression
and biological properties [3]. Furthermore, the bio-
logical properties of ASCs are influenced by systemic
disease such as diabetes. ASCs isolated from type 2 dia-
betics exhibit elevated levels of cellular senescence and
apoptosis, as well as altered differentiation capacity
[13]. Similarly, Cianfarani et al. [14] reported that stro-
mal vascular fractions (SVFs) isolated from diabetic ani-
mals exhibit several alterations. In material obtained
from diabetic donors, the percentage of cells expressing
stem cell-specific membrane markers in SVFs and cul-
tured cells is reduced. Moreover, the levels of vascular
endothelial growth factor (VEGF)-A, hepatocyte growth
factor (HGF), and insulin-like growth factor (IGF)-1 in
the conditioned medium of diabetic ASCs are also re-
duced. These observations suggest that diabetic ASCs
suffer from impairments in the ability to produce or re-
lease factors that mediate cell signaling [15].
Recently, platelet-rich plasma (PRP) was introduced in
tissue engineering as a source of large quantities of growth
factors, and this material has been applied as a novel
matrix to enhance the properties of transplanted cells.
PRP has been used clinically in humans since the 1970s
for its wound-healing properties, which are attributed to
its high levels of growth factors and secretory proteins
[16]. The growth factors in PRP promote the recruitment,
proliferation, and differentiation of cells involved in tissue
regeneration [17].
Preclinical studies using ASCs and PRP in combin-
ation have been conducted in the contexts of periodontal
tissue engineering [18, 19], wound healing [20], tendon
repair [21], and bone regeneration [22]. These reports
demonstrate the potential of PRP as a cell carrier (scaf-
fold) to increase the potential of the transplanted cells
used in stem cell therapies. Therefore, it is possible that
PRP could contribute to stem cell therapies.
The purpose of this article is to describe the basic sci-
ence of ASCs and PRP, the potential benefits of adding
PRP to ASCs, and preclinical and clinical studies in vari-
ous medical fields. We also discuss the mechanisms ofPRP action and future cell-based therapies using co-
transplantation of ASCs and PRP.
Characterization of adipose-derived stem cells
Adipose tissue contains SVFs including pre-adipocytes,
fibroblasts, vascular smooth muscle cells, endothelial
cells, resident monocytes/macrophages, lymphocytes and
ASCs, and is composed mainly of fat cells organized into
lobules [23, 24].
Stem cell yields from adipose tissue are greater than
those from other stem cell reservoirs, making them
especially suitable for use in regenerative medicine.
Routinely, 107 adipose stromal/stem cells can be iso-
lated from 300 ml of lipoaspirate with greater than
95 % purity [23, 25]. ASCs comprise approximately 2 %
of the nucleated cells in processed lipoaspirate, and the
yield of ASCs is approximately 5000 fibroblast colony-
forming units (CFU-F) per gram of adipose tissue, com-
pared with approximately 100 to 1000 CFU-F per ml of
bone marrow [26].
In 2006, the International Society for Cellular Therapy
proposed minimal phenotypic criteria for the definition
of cultured MSCs. The main criteria for MSCs are: (1)
adhesion to plastic; (2) more than 95 % of the MSC
population must express CD73, CD90, and CD105 and
their population must lack expression of CD34, CD45,
CD11b or CD14, CD79 or CD19, and HLA class II (less
than 2 % should express these); and (3) tri-lineage differ-
entiation potential [27, 28]. In its position statement, the
Society also specified CD34 as a negative marker for
MSCs [27], but recent reports show that this marker must
be evaluated in the context of the tissue from which the
MSCs were isolated.
Reports of the percentage of SVF cells expressing
CD34 vary greatly [29–32]. Up to 85 % of the cells in
SVFs express CD34 [30, 33, 34]. Two days after plastic
adherence, more than 95 % of cells express CD34, co-
express mesenchymal (CD10/CD13/CD90) and pericytic
markers (CD140a and -b), and are CD31–/CD45– [35].
Furthermore, distinct CD34+ subpopulations have been
described [30, 31, 36].
Factors that decrease stemness in adipose-derived stem
cells
ASCs can be expanded ex vivo in a relatively short period
of time [37–39]; however, their ‘stemness’, defined by their
potential to proliferate and differentiate, gradually de-
creases during serial passage [37].
The differentiation capacity of ASCs may not be in-
volved in their primary regenerative mechanism in cell
therapy; however, the multipotent character of these
preparations has been demonstrated in vitro and is the
main focus of attention in the context of their use in
tissue engineering [3]. ASCs secrete cytokines, growth
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effects in response to local microenvironmental cues,
and these factors are likely to mediate the main mech-
anisms underlying the regenerative and repair potential
of these cells [40]. However, a large number of studies
show that cultured ASC preparations are heteroge-
neous and consist of different populations of stem and
progenitor cells with self-renewal properties and multi-
potent differentiation profiles [2]. The heterogeneity of
ASC preparations may be due to various causes, including
inter-donor differences in age, body mass index, gender,
ethnicity, and disease status [1]. Sethe et al. [41] re-
ported that MSCs from older donors show no spindle-
shaped morphology in culture compared with MSCs
from younger donors. In another report, Xu et al. [42]
demonstrated that the osteogenic differentiation poten-
tial of ASCs is related to donor age. Body mass index
correlates negatively with the number of stromal cells
per gram and their differentiation capacity [1]. In
addition, Gimble et al. [43] suggested that brown adi-
pose tissue and white adipose tissue show different
capacities with regard to cell proliferation and yield of
stem cells. Furthermore, epigenetic changes affect stem
cell growth and cell differentiation potential. Yan et al.
[44] reported that pretreatment with 5-azacytidine im-
proved proliferation and osteogenic differentiation of
ASCs from older donors.
In particular, systemic diseases such as diabetes influ-
ence the properties of ASCs. Because the hyperglycemic
diabetic environment may impact aspects of stemness,
including the phenotype, morphology, and differenti-
ation potential of ASCs, the potential use of autologous
cell therapies in diabetic patients has caused contro-
versy. Several studies demonstrate that the ASCs from
diabetics have impaired function relative to ASCs from
non-diabetic donors [15]. In ASCs from diabetic rats,
for example, MSC markers are downregulated, and via-
bility and differentiation potential are reduced [45, 46].
Based on the reduced proliferative potential and migra-
tion and limited therapeutic potential of autologous
ASCs when administered to wounds of diabetic mice,
some authors have questioned the efficiency of autolo-
gous therapies in diabetic patients [14, 47]. In an
in vivo study, ASCs from streptozotocin-induced type 1
diabetic mice exhibited reduced proliferative potential
and migration, and diabetic ASCs released lower amounts
of HGF, VEGF-A, and IGF-1 [14]. Although autologous
ASC administration improves healing in diabetic skin re-
pair [48], functional impairment in resident and recruited
cells strongly contributes to delayed wound healing in dia-
betic subjects [49–54]. Therefore, it is essential to evaluate
the impact of the diabetic milieu on clinical applications
of ASCs. In a clinical trial in which autologous ASCs were
used for the treatment of critical limb ischemia, ASCsfrom diabetic patients had fibrinolytic activity, which was
suggested to cause peripheral microthrombosis [55].
Factors that increase stemness in adipose-derived stem
cells, and the potential of platelet-rich plasma
Recent reports suggested that certain growth factors,
such as vascular VEGF, fibroblast growth factor (FGF)-2,
FGF-4, FGF-6, FGF-7, FGF-9, FGF-17, transforming
growth factor (TGF)-beta1, TGF-beta2, HGF, keratino-
cyte growth factor, platelet-derived growth factor AA,
and IGF-1, regulate the maintenance of ASC stemness
[37]. These factors affect a plethora of responses such as
angiogenesis, cellular migration, apoptosis, proliferation,
and differentiation [56–59]. In particular, the prolifera-
tion of ASCs is regulated by paracrine factors such as
FGF-2, FGF-4, interleukin (IL)-6, and stromal-derived
factor 1, whereas FGF-2, endothelial growth factor, TGF-
beta, and other factors are involved in differentiation
[60, 61].
Platelets contain critical growth factors and mediators
of tissue repair pathways. Activation of platelets with
calcium chloride induces immediate platelet growth fac-
tor release in vitro [62]. PRP obtained from autologous
blood contains a high concentration of stored autologous
growth factors. Exposure of PRP to calcium chloride
induces platelet degranulation. Several studies describe
the potential benefits of using PRP in tissue regeneration;
in particular, PRP therapy has been proposed in wound
healing. Moreover, because PRP is able to stimulate prolif-
eration of undifferentiated stem cells as well as cell differ-
entiation, it might be used in conjunction with stem cell
transplantation to promote tissue regeneration [63–66].
However, although the biological mechanism and clin-
ical effect of PRP remain poorly understood, some studies
on the mechanism of action of PRP have been reported
recently. Andia et al. [67] demonstrated that human PRP
induces an immunomodulatory and proangiogenic pheno-
type consistent with healing mechanisms of inflamed
tenocytes in vitro. The expression of some crucial inflam-
matory molecules, including IL-6 and IL-8, was downreg-
ulated in response to PRP treatment.
Furthermore, various methods for manipulating PRP
have been reported. For example, the platelet concentra-
tion in plasma [68], the volume of PRP transplantation,
and the method of activation contribute to the effect of
PRP on cell proliferation and differentiation directly. For
these reasons, appropriate methods when using PRP are
still controversial.
On the other hand, the fibrin network of PRP has the
potential to serve as a scaffold. We have shown that
this network can hold cells and platelets in a three-
dimensional arrangement within the PRP (Fig. 1). This
cell–PRP interaction may increase stemness and pro-
long the survival time and rate of cells in the PRP.
Fig. 1 a Low-magnification scanning electron microscopy (SEM) image
of a mixture of adipose-derived stem cells (ASCs) with activated platelet-
rich plasma (PRP). Some ASCs are arranged three-dimensionally in the
fibrin network of the activated PRP. b High-magnification SEM image of
panel a. Some platelets reside around the ASCs. Arrows indicate ASCs
and double arrows indicate platelets
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represents an attractive approach for autologous cell
therapies.
Preclinical and clinical studies using adipose-derived stem
cells and platelet-rich plasma
Recently, research comparing ASCs alone or in combin-
ation with PRP have been reported. Kim et al. [69] com-
pared fat graft survival with PRP, ASCs, and SVFs in a
mouse model. Transplanted fat tissue with ASCs or SVFs
was effective in preventing volume reduction of fat tissue
compared with conventional fat graft or adding PRP. In
another study, human ASCs or adipocytes were cultured
with PRP in vitro [70]. The results showed that ASC via-
bility was strongly increased in the presence of 5 % or
20 % PRP. Furthermore, levels of IL-6, IL-8, IL-10, VEGF
and interferon-γ were significantly increased in PRP-
treated adipocytes [70]. Atashi et al. [71] reported that20 % PRP was the most effective concentration to pro-
mote ASC proliferation. Recently, Xu et al. [42] reported
that activated PRP promoted proliferation and differenti-
ation of human ASCs in vitro. Interestingly, the effects of
PRP on ASC proliferation and osteogenic differentiation
were dose-dependent.
Recently, co-transplantation of ASCs and PRP has
been extensively investigated, and the role of PRP factors
as powerful paracrine effectors in ASC transplantation
has been demonstrated in preclinical and clinical studies
(Table 1).
Numerous preclinical studies have demonstrated the
efficacy of co-transplantation of ASCs and PRP in a wide
range of model systems. Van Pham et al. [72] trans-
planted ASCs cultured with 15 % PRP into the articular
cartilage injury model of NOD/SCID mice. Their results
showed that PRP-pretreated ASCs improved healing of
injured articular cartilage more effectively than un-
treated ASCs. In a bone regeneration study, Tajima
et al. [22] transplanted rat ASCs and PRP into a rat cal-
varial defect model. They found that co-transplantation
of ASCs and PRP significantly improved bone regener-
ation; furthermore, 8 weeks after transplantation, the
volume of regenerated bone was significantly greater
when PRP and ASCs were transplanted together than
when PRP or ASCs in collagen gel were used alone. In
another study, Tobita et al. [18] transplanted a combin-
ation of rat ASCs and PRP into a periodontal tissue
defect in Wistar rats. Eight weeks after this treatment,
histological observation revealed regeneration of alveo-
lar bone, periodontal ligament-like structures, and
cementum-like structures in the periodontal tissue de-
fect. Likewise, when canine-derived ASCs were trans-
planted with PRP, regeneration of these periodontal
tissues was greatly improved relative to PRP-treated or
saline-treated control subjects 8 weeks after transplant-
ation [19]. Tobita and Mizuno [24] transplanted uncul-
tured human SVFs, taken from subcutaneous fat tissue,
along with PRP into a periodontal tissue defect in nude
rats; this treatment resulted in extensive improvement
of periodontal tissue 8 weeks after transplantation. A
recent study reported the transplantation of a combin-
ation of ASCs and PRP for treatment of bisphosphonate-
related osteonecrosis of the jaw in a rat model [73]. The
results demonstrated that a lower frequency of osteo-
necrosis was associated with the combination of ASCs
and PRP.
Likewise, in clinical studies, combined transplantation
of ASCs and PRP has shown great promise. Koh et al.
[74] injected a combination of ASCs and PRP into 18
patients with osteoarthritis or degenerative cartilage,
and found that this treatment effectively reduced pain
and improved knee function in patients being treated
for knee osteoarthritis. Pak et al. [75] investigated the
Table 1 Preclinical and clinical studies using adipose-derived stem cells and platelet-rich plasma
Type of cells
(SVFs or ASCs)
Species of cells How to use
the PRP
Animal model/disease Results Reference
Preclinical studies
ASCs Human Co-administration Mouse full thickness
wound model
Co-administration of PRP and ASCs
in the wound beds increased ASC
survival and enhanced arteriole
formation in wounds
[20]
ASCs Rat (Wistar) Co-administration Osteonecrosis of
the jaw
The combination of ASCs and PRP
prevented frequency of bisphosphonate-
related osteonecrosis of the jaw
[73]
ASCs Rabbit Co-transplantation Achilles tendon
injured model
ASCs differentiated into tenocytes [21]
ASCs Human ASCs were treated




PRP-treated ASCs improved healing
of injured articular cartilage
[72]
ASCs Rat (Fischer) Co-transplantation Rat calvarial defect Regenerated volume of bone was
significantly greater than in the
PRP-treated group and ASCs/
collagen gel-treated group 8 weeks
after transplantation
[22]
ASCs Rat (Wistar) Co-transplantation Rat periodontal
tissue defect
Alveolar bone, periodontal ligament-
like structures, and cementum-like
structures were observed in the
periodontal tissue defect 8 weeks
after transplantation
[18]
ASCs Canine Co-transplantation Canine periodontal
tissue defect
Periodontal tissue regeneration was
observed in the bifurcation defect
8 weeks after transplantation
[19]
SVFs Human Co-transplantation Rat periodontal
tissue defect




ASCs Human Co-transplantation Osteoarthritis 18 patients were treated. Intra-articular
injection of a combination of ASCs and
PRP effectively reduced pain and improved
knee function in patients being treated for
knee osteoarthritis
[74]
SVFs Human Co-transplantation Articular joints 91 patients were treated with autologous
SVFs with PRP over 2 years
[75]
ASC adipose-derived stem cell; PRP platelet-rich plasma; SVF stromal vascular fraction
Note: This article is part of a thematic series ‘Mesenchymal
Stem/Stromal Cells—An update’. Other articles in this series can
be found at http://www.biomedcentral.com/series/mesenchymal
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ticular joints; in this study, 91 patients were treated
with a combination of autologous SVFs with PRP over
the course of 2 years.
Conclusion
ASCs hold great potential for use in stem cell therapy.
After being transplanted, however, ASCs face a complex
and hostile environment in which local hypoxia, oxida-
tive stress, and inflammation may lead to cell loss or
death on a large scale. Furthermore, the stemness prop-
erties of ASCs are influenced by the disease state of the
donor. Insufficient retention and survival of transplanted
ASCs can dramatically reduce their therapeutic effects
[76]. Therefore, tissue engineering approaches need to
be dramatically improved by the addition of adjuncts
that increase the proliferation and differentiation ofASCs. In this regard, PRP is an attractive cell-maintained
biomaterial, and the activated PRP scaffold can enhance
the stemness properties of ASCs, although further ana-
lysis and investigation are needed to establish novel cell
therapies.
In particular, risk assessments of cell transplantation in
clinical studies are especially important because clinical ef-
ficacy and safety depend on the manipulation of various
factors, culture conditions, and quality risk management.
The evidence compiled to date suggests that this com-
bination treatment represents a promising approach in
various fields of medicine and dentistry.
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